Related Experiment Videos

Treatment of acute myocardial infarction with streptokinase does not appear to modulate circulating neutrophil

S A Adams1, S P Froese, B K Green

  • 1Department of Medicine, University of Cape Town, South Africa.

Clinical Cardiology
|August 1, 1995
PubMed

Insights

Streptokinase therapy for acute myocardial infarction (AMI) increases fibrin degradation products and white blood cells. However, it did not significantly alter neutrophil function, adhesion, or expression markers in AMI patients.

Area of Science:

  • Cardiology
  • Immunology
  • Hematology

Background:

  • Thrombolytic therapy is standard for acute myocardial infarction (AMI) to restore coronary artery patency.
  • Thrombolytic agents and fibrinolysis byproducts may exacerbate myocardial damage by affecting neutrophil function.
  • Understanding streptokinase's impact on neutrophil behavior is crucial for managing AMI.

Purpose of the Study:

  • To investigate the effect of streptokinase administration on circulating neutrophil function in patients with AMI.
  • To assess changes in neutrophil adherence, aggregation, and surface marker expression (CD11b, L-selectin) post-thrombolysis.
  • To compare neutrophil function in AMI patients receiving streptokinase with healthy controls.

Main Methods:

  • Monitored neutrophil adherence to endothelial cells and homotypic aggregation.
  • Measured CD11b and L-selectin expression on neutrophils before and 6 hours after streptokinase therapy.
  • Included AMI patients treated with aspirin and streptokinase, and healthy controls on aspirin only.

Main Results:

  • Streptokinase administration led to a marked increase in circulating fibrin degradation products and white blood cells (leukocytosis).
  • No significant differences were observed in neutrophil adherence, aggregation, CD11b, or L-selectin expression between pre- and post-therapy neutrophils in AMI patients.
  • Neutrophil function markers did not differ significantly between AMI patients and healthy controls.

Conclusions:

  • Streptokinase induces acute neutrophil leukocytosis and elevates fibrin degradation products in AMI patients.
  • The study's assays did not detect significant changes in neutrophil adhesion or activation markers following streptokinase therapy in AMI.
  • These findings suggest streptokinase may not significantly impair neutrophil function in the context of AMI, despite observed leukocytosis.

Related Concept Videos